Last week, a New York judge called a halt on Actavis' plan to pull Namenda off the market, throwing off its strategy for switching patients to a newer extended-release version.
Point-of-care marketing is shooting past direct-to-consumer advertising as pharma marketing's latest trend.
Germany's cost-effectiveness watchdog said Bayer eye drug Eylea doesn't perform any better than its Novartis rival, Lucentis, as a treatment for diabetic macular edema.
A new study shows that awareness campaigns can work--and work well. During a three-month push for lung cancer testing in the U.K., primary care doctors referred more than 3,000 extra patients to get tested. About 700 were diagnosed with lung cancer.
Indian drugmaker Zydus Cadila has launched a biosimilar of Humira in its home market--the first in a long line of in-development copies to threaten AbbVie's powerhouse med.
Even a megablockbuster launch isn't enough to save Novartis sales reps targeted for job cuts. The company is laying off 200 primary care sales folks in New Jersey as it rejigs its sales operation and prepares to launch LCZ696, a hotly anticipated heart failure drug.
The flu season's most common viral strain has mutated, meaning this year's shots may not fully protect against it. But the so-called "drifted" strain may open up an opportunity for antiviral makers like Roche's Genentech and GlaxoSmithKline, with the CDC urging earlier use of anti-flu drugs to combat potentially severe symptoms.
How did Genentech persuade physicians to switch from $50-a-dose Avastin to $2000-a-dose Lucentis? According to The New York Times, consultation payments may have had something to do with it.
As shareholders gear up to vote on Reckitt Benckiser's plan to spin off its ailing pharma division, company execs are gearing up to double down on consumer health. And though a handful of pharma heavyweights are targeting the field with renewed focus, the British OTC giant believes it has the edge.
In October, the Sanofi board fired CEO Chris Viehbacher. Now, a whistleblower lawsuit claims that part of Viehbacher's undoing was tied to a massive kickback scheme directed through consultants that was used to juice sales of diabetes meds in the States.